About Aravax
Revolutionising the treatment of food allergies with safer and more convenient next-generation immunotherapies.
Aravax is a clinical stage biotechnology company dedicated to revolutionising the treatment of food allergies with next-generation, disease-modifying immunotherapies which are safer and more convenient than existing approaches
Clinical Pipeline
Our lead product, PVX108 is currently being studied in an international Phase 2 trial for the treatment of peanut allergy. We are also leveraging our proprietary platform technologies and know-how to develop a pipeline of immunotherapies to tackle other significant food allergy indications.
Our Proprietary Platform
Aravax’s next-generation immunotherapies use proprietary peptides designed to precisely retrain the immune system to tolerate specific foods whilst avoiding treatment-induced acute allergic reactions.
Investors
We are backed by a strong syndicate of leading international and Australian investors including Novartis Venture Fund, Brandon Capital, Tenmile, Breakthrough Victoria, Uniseed and UniSuper.
Global Operations
Aravax is an international company located in Melbourne, Australia and Oxford, UK with operations in USA and Europe.
The company was founded in 2015 from technology and Intellectual property from Alfred Health and Monash University, Melbourne.
